Partnership Extends Cell Line offering in South Korea

Strengthening its presence in the Asia-Pacific region, Fusion Antibodies has appointed A-Frontier as exclusive supplier in South Korea for its discovery, engineering and cell line development services, which include proprietary platforms for Humanisation and Affinity Maturation. A-Frontier is a leading supplier in Korea with its own R&D centre delivering custom antibody and protein related service.

Paul Kerr, CEO, Fusion Antibodies (Belfast) said, “We are delighted to announce this partnership with A-Frontier. We recognise their quality organisation and service provision and extensive network in the Biotech field and are excited to have our platforms offered to their customers. This partnership will connect us with companies carrying out innovative work in drug discovery in South Korea. We look forward to working closely with companies to help them get to the clinic as quickly as possible without compromising the quality of their antibody.”

Eonjung Kim, CEO, A-Frontier said, “We are pleased to be able to offer these unrivalled platforms to our customers and are happy that Fusion Antibodies have selected us to deliver their services in this region.”